DOJ files 2 Mississippi civil complaints tied to 2026 takedown—CSA claims

On July 17, 2026, the U.S. Attorney’s Office for the Southern District of Mississippi announced two newly filed civil complaints tied to the Department of Justice’s 2026 National Health Care Fraud Takedown. According to DOJ, the complaints seek civil and monetary penalties under the Controlled Substances Act (CSA)—using recordkeeping, inventory, and dispensing-practice theories that regulators often link to diversion and patient-safety concerns.

These are allegations in complaints. They have not been proven in court.

Case 1: DOJ says Clint’s Pharmacy couldn’t account for 11,853 pills

In the first complaint, DOJ alleges Clint’s Pharmacy (formerly owned and operated by Clint Bane)—located in Brookhaven, Mississippi—could not account for 11,853 controlled-substance pills after on-site regulatory inspections. DOJ says each unaccounted pill constitutes a CSA recordkeeping violation and frames the case around two types of CSA claims:

• Refusal to comply with CSA record-keeping requirements, which DOJ says carries a penalty of up to $19,246 for each violation.
• Unlawful dispensing of a controlled substance, which DOJ says carries a penalty of up to $82,950 for each violation.

Case 2: DOJ alleges negligent dispensing and record/inventory failures tied to 433,000+ substances

The second complaint names Rommel Asagwara and Lemmor Holdings, LLC d/b/a Dream Weight Clinic. DOJ alleges Asagwara negligently dispensed controlled substances outside the usual course of professional practice. The complaint also alleges the defendants failed to keep controlled substances at the registered location and failed to maintain adequate records and inventory for over 433,000 controlled substances.

DOJ says it is seeking over $8 billion for each of the 433,000 unaccounted-for pills and other CSA violations (as stated in the press release).

How DOJ links these Mississippi filings to the 2026 national takedown

DOJ explicitly ties the July 17, 2026 civil complaints to the broader 2026 National Health Care Fraud Takedown. In DOJ Office of Public Affairs materials dated June 23, 2026, DOJ described the initiative as resulting in charges against 455 defendants involving over $6.5 billion in alleged false claims and related patient harm.

The reader takeaway: DOJ’s strategy here is not only to pursue fraud theories, but also to press CSA-focused enforcement when controlled-substance accounting, inventory, and dispensing practices are alleged to have failed.

What to watch next in federal court

Because these cases begin as civil complaints, the next steps can include defendants’ responses and motions, followed by discovery and pretrial proceedings. Court scheduling orders can be especially important for understanding what documents will be sought and when key hearings or rulings are expected.

What to monitor:

• Defendants’ answers and early motions responding to DOJ’s CSA allegations.
• Court scheduling orders setting deadlines for discovery and pretrial filings.
• Any DOJ updates that indicate whether the cases move toward settlement or continued litigation.

Why CSA recordkeeping and inventory claims can matter for public health and consumer costs

Controlled-substance compliance depends on dependable accounting and inventory controls. When DOJ alleges large gaps in what a facility can account for, investigators and regulators may have fewer reliable checks for diversion and for whether prescribing/dispensing decisions were made within expected professional practice.

Beyond safety, these enforcement actions can also affect consumer health-care costs indirectly—through compliance remediation expenses, litigation costs, provider operational changes, and broader scrutiny that can influence how clinics and pharmacies handle controlled substances.

Sources

• Southern District of Mississippi — July 17, 2026 press release on the two civil complaints